Research Article
A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies
Figure 17
Quantification of the ADCC activity of infliximab using ready-to-use iLite effector cells or thaw-and-use NFAT effector cells and mTNFα target cells. RTU iLite effector cells (1.2 × 105 cells/well) and mTNFα target cells were mixed at an E:T ratio of 6 : 1 and incubated for 4, 6, or 18 hours at 37°C in the presence of increasing concentrations of infliximab (a), RTU iLite effector cells (1.2 × 105 cells/well) or thaw-and-use NFAT responsive effector cells (0.75 × 105 cells/well), and RTU mTNFα target cells were mixed at an E:T ratio of 6 : 1 and incubated for 6 hours at 37°C in the presence of increasing concentrations of infliximab (b) prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. Results are expressed as fold induction of FL activity.
| (a) |
| (b) |